Atezolizumab and hyaluronidase-tqjs

Drug Overview

Atezolizumab and hyaluronidase-tqjs is a fixed-dose combination of a programmed death-ligand 1 (PD-L1) blocking antibody and an endoglycosidase. It is the first and only subcutaneous (under the skin) injection of a PD-(L)1 inhibitor approved for cancer immunotherapy, offering a significantly faster administration time compared to the traditional intravenous infusion.

• Generic Name: Atezolizumab and hyaluronidase-tqjs
• US Brand Names: Tecentriq Hybreza™
• Drug Class: PD-L1 Blocking Antibody and Endoglycosidase
• Route of Administration: Subcutaneous (SC) Injection
• FDA Approval Status: Approved for multiple indications, including Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Hepatocellular Carcinoma (HCC), Melanoma, and Alveolar Soft Part Sarcoma (ASPS).

What Is It and How Does It Work? (Mechanism of Action)

This drug combines the established immunotherapy mechanism of atezolizumab with a novel delivery technology that allows large-volume biologics to be injected under the skin.

• Immune Checkpoint Blockade (Atezolizumab): The active therapeutic component is atezolizumab, a monoclonal antibody that targets PD-L1 (Programmed Death-Ligand 1). By binding to PD-L1 on tumor cells and tumor-infiltrating immune cells, it blocks the interaction with the PD-1 and B7.1 receptors. This releases the “brakes” on the immune system, reactivating T-cells to recognize and kill cancer cells.
• Drug Delivery Facilitator (Hyaluronidase-tqjs): The second component is an enzyme that temporarily degrades hyaluronan, a barrier substance in the subcutaneous tissue. This degradation increases the permeability of the tissue, creating space for the large volume (15 mL) of atezolizumab to be rapidly dispersed and absorbed into the bloodstream. This effect is reversible, and the hyaluronan is restored within 24-48 hours.

FDA-Approved Clinical Indications

Atezolizumab and hyaluronidase-tqjs are approved for all adult indications previously established for the intravenous formulation of atezolizumab.

Oncological Uses:

• Non-Small Cell Lung Cancer (NSCLC):
  • Adjuvant treatment following resection and platinum-based chemotherapy for Stage II-IIIA tumors with PD-L1 expression ≥1%.
  • First-line treatment for metastatic NSCLC with high PD-L1 expression (single agent).
  • First-line treatment for metastatic non-squamous NSCLC (in combination with bevacizumab/chemotherapy).
  • Treatment of metastatic NSCLC after disease progression on platinum-containing chemotherapy.
• Small Cell Lung Cancer (SCLC): First-line treatment of extensive-stage SCLC in combination with carboplatin and etoposide.
• Hepatocellular Carcinoma (HCC): First-line treatment of unresectable or metastatic HCC in combination with bevacizumab.
• Melanoma: Treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma in combination with cobimetinib and vemurafenib.
• Alveolar Soft Part Sarcoma (ASPS): Treatment of unresectable or metastatic ASPS in adults.

Non-Oncological Uses:

• There are no FDA-approved non-oncological indications.

Dosage and Administration Protocols

Unlike the IV version, this formulation is a fixed dose administered subcutaneously in the thigh. It must not be administered intravenously.

Standard Oncology Dosage:

• Preparation: The vial must be removed from the refrigerator and allowed to reach room temperature before injection.
• Injection Time: Administered over approximately 7 minutes.
• Frequency: Every 3 weeks (q3w).

Note: For patients transitioning from IV atezolizumab to SC, the first SC dose should be administered on the day the next IV dose would have been due.

Clinical Efficacy and Research Results

The approval of this formulation was based on pivotal Phase III data demonstrating that the subcutaneous route is as effective as the intravenous route.

• Non-Inferiority (IMscin001 Trial): In a global Phase III randomized study involving patients with locally advanced or metastatic NSCLC, subcutaneous administration demonstrated non-inferior pharmacokinetics (Ctrough and AUC) compared to the standard IV infusion. The efficacy endpoints, including Overall Response Rate (ORR) and Progression-Free Survival (PFS), were consistent between the two arms.
• Survival Data: Updated analysis showed comparable Median Overall Survival (OS) between the subcutaneous arm (10.7 months) and the intravenous arm (10.1 months) (Hazard Ratio: 0.88), confirming that changing the route of administration does not compromise survival outcomes.
• Patient Preference: Studies indicate that the majority of patients prefer the subcutaneous option due to reduced time in the clinic (minutes vs. hours) and less invasive administration compared to finding a vein for IV infusion.

Safety Profile and Side Effects

Important Warnings:

While generally well-tolerated, this drug carries warnings for Severe and Fatal Immune-Mediated Adverse Reactions and Hypersensitivity to hyaluronidase.

Common Side Effects (>10%)

• Injection Site Reactions: Redness, pain, or swelling at the injection site (thigh) is specific to this formulation but usually mild.
• General: Fatigue (very common), decreased appetite, and nausea.
• Respiratory: Cough and dyspnea (shortness of breath).
• Musculoskeletal: Musculoskeletal pain.

Serious Adverse Events

• Immune-Mediated Pneumonitis: Inflammation of the lungs (3% incidence), which can be fatal. Patients with a new cough must be evaluated immediately.
• Immune-Mediated Hepatitis: Liver inflammation requiring regular monitoring of liver enzymes (AST/ALT/Bilirubin).
• Endocrinopathies: Thyroid disorders (hypo/hyperthyroidism) and Type 1 Diabetes Mellitus have been reported.
• Severe Hypersensitivity: Anaphylactic reactions to the hyaluronidase component can occur. It is contraindicated in patients with known hypersensitivity to hyaluronidase.

Management Strategies:

• For Immune-Mediated Reactions: Withhold treatment for Grade 2; permanently discontinue for Grade 3 or 4. Administer corticosteroids (prednisone 1-2 mg/kg/day) for severe reactions.
• For Injection Site Reactions: Rotate injection sites (left vs. right thigh). Do not inject into skin that is red, bruised, or tender.

Connection to Stem Cell and Regenerative Medicine

Atezolizumab and hyaluronidase-tqjs have critical interactions with stem cell transplantation due to their mechanism of immune activation.

• Complications of Allogeneic HSCT: The FDA label includes a specific warning regarding Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Using PD-1/PD-L1 inhibitors before or after an allogeneic transplant can lead to severe Graft-versus-Host Disease (GVHD) and hepatic Veno-Occlusive Disease (VOD). The activated T-cells may aggressively attack the donor stem cells or the recipient’s healthy organs, leading to fatal complications.
• Regenerative Tissue Permeability: The hyaluronidase component is an enzyme used in regenerative medicine to modify the extracellular matrix. By temporarily breaking down hyaluronan, it modulates tissue permeability, a principle also explored in regenerative therapies to improve the diffusion of stem cells or gene therapies into dense tissues.

Patient Management & Practical Recommendations

Pre-Treatment Tests:

• PD-L1 Testing: Required for specific NSCLC indications to determine eligibility.
• Liver Function & Thyroid Panel: Baseline assessment is mandatory to monitor for immune-mediated toxicity.
• Pregnancy Test: Verify negative status in females of reproductive potential.

Precautions During Treatment:

• Injection Site Care: Patients should wear loose clothing (shorts/skirt) to the appointment to allow easy access to the thigh. They should not rub the injection site after administration.
• Hypersensitivity Monitoring: Patients must be monitored for signs of allergic reaction (rash, wheezing) during and shortly after the injection.

Do’s and Don’ts:

• DO: Rotate the injection site between the left and right thigh for each dose.
• DO: Report any cough, shortness of breath, or diarrhea immediately, as these can be signs of serious immune-mediated conditions.
• DON’T: Administer the drug intravenously; it is formulated strictly for subcutaneous use.
• DON’T: Inject into areas with tattoos, scars, or active skin infections.

Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.